Key result
Administration of a physiologic dose of chromogranin A prevented doxorubicin-induced cardiotoxicity without impairing its anticancer activity in murine models.
Why the study?
Clinical use of doxorubicin is limited by dose-dependent cardiotoxicity, prompting investigation into whether chromogranin A can regulate its cardiotoxic and antitumor activities.
Does a physiologic dose of chromogranin A prevent doxorubicin-induced cardiotoxicity without impairing its anticancer activity in animal models?
Does a physiologic dose of chromogranin A prevent doxorubicin-induced cardiotoxicity without impairing its anticancer activity in animal models?
Administration of low-dose chromogranin A may represent a novel approach to prevent doxorubicin-induced cardiotoxicity without compromising its antitumor efficacy.
Answers are grounded in this paper and cite their sources.
May warrant clinical evaluation of chromogranin A for doxorubicin cardioprotection; leaves open confirmation in human trials.
The clinical use of doxorubicin (Doxo), a widely used anticancer chemotherapeutic drug, is limited by dose‐dependent cardiotoxicity. We have investigated whether chromogranin A (CgA), a cardioregulatory protein released in the blood by the neuroendocrine system and by the heart itself, may contribute to regulation of the cardiotoxic and antitumor activities of Doxo. The effects of a physiologic dose of full‐length recombinant CgA on Doxo‐induced cardiotoxicity and antitumor activity were investigated in rats using in vivo and ex vivo models and in murine models of melanoma, fibrosarcoma, lymphoma, and lung cancer, respectively. The effect of Doxo on circulating levels of CgA was also investigated. In vivo and ex vivo mechanistic studies showed that CgA can prevent Doxo‐induced heart inflammation, oxidative stress, apoptosis, fibrosis, and ischemic injury. On the other hand, CgA did not impair the anticancer activity of Doxo in all the murine models investigated. Furthermore, we observed that Doxo can reduce the intracardiac expression and release of CgA in the blood ( i.e ., an important cardioprotective agent). These findings suggest that administration of low‐dose CgA to patients with low levels of endogenous CgA might represent a novel approach to prevent Doxo‐induced adverse events without impairing antitumor effects.—Rocca, C., Scavello, F., Colombo, B., Gasparri, A. M., Dallatomasina, A., Granieri, M. C., Amelio, D., Pasqua, T., Cerra, M. C., Tota, B., Corti, A., Angelone, T. Physiological levels of chromogranin A prevent doxorubicin‐induced cardiotoxicity without impairing its anticancer activity. FASEB J. 33, 7734–7747 (2019). www.fasebj.org
No takes yet. Share an insight, caveat, or question.
Rocca et al. (2019) studied Doxorubicin-induced cardiotoxicity and cancer. Chromogranin A (CgA) was evaluated on Doxorubicin-induced heart inflammation, oxidative stress, apoptosis, fibrosis, ischemic injury, and antitumor activity. Administration of a physiologic dose of chromogranin A prevented doxorubicin-induced cardiotoxicity without impairing its anticancer activity in murine models.
Synapse has enriched 10 related papers. Consider them for comparative context: